IL325945A - תרופות רדיואקטיביות המכוונות ל-psma לטיפול בסרטן - Google Patents

תרופות רדיואקטיביות המכוונות ל-psma לטיפול בסרטן

Info

Publication number
IL325945A
IL325945A IL325945A IL32594526A IL325945A IL 325945 A IL325945 A IL 325945A IL 325945 A IL325945 A IL 325945A IL 32594526 A IL32594526 A IL 32594526A IL 325945 A IL325945 A IL 325945A
Authority
IL
Israel
Prior art keywords
psma
cancer
treatment
targeted radiopharmaceuticals
radiopharmaceuticals
Prior art date
Application number
IL325945A
Other languages
English (en)
Inventor
Kevin Roland
Ian Ruixiang Duffy
Rajiv Bhalla
Original Assignee
Fusion Pharmaceuticals Inc
Kevin Roland
Ian Ruixiang Duffy
Rajiv Bhalla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc, Kevin Roland, Ian Ruixiang Duffy, Rajiv Bhalla filed Critical Fusion Pharmaceuticals Inc
Publication of IL325945A publication Critical patent/IL325945A/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)
IL325945A 2023-07-27 2024-07-26 תרופות רדיואקטיביות המכוונות ל-psma לטיפול בסרטן IL325945A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363515943P 2023-07-27 2023-07-27
PCT/CA2024/050996 WO2025019952A1 (en) 2023-07-27 2024-07-26 Psma-targeted radiopharmaceuticals for treatment of cancer

Publications (1)

Publication Number Publication Date
IL325945A true IL325945A (he) 2026-03-01

Family

ID=94373788

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325945A IL325945A (he) 2023-07-27 2024-07-26 תרופות רדיואקטיביות המכוונות ל-psma לטיפול בסרטן

Country Status (10)

Country Link
KR (1) KR20260043111A (he)
CN (1) CN121752301A (he)
AR (1) AR133391A1 (he)
AU (1) AU2024298849A1 (he)
CO (1) CO2026002011A2 (he)
DO (1) DOP2025000324A (he)
IL (1) IL325945A (he)
MX (1) MX2026000917A (he)
TW (1) TW202510848A (he)
WO (1) WO2025019952A1 (he)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers
US11541134B1 (en) * 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
CN118946371A (zh) * 2022-01-28 2024-11-12 融合制药公司 靶向psma的放射性药物和检查点抑制剂的组合疗法

Also Published As

Publication number Publication date
KR20260043111A (ko) 2026-03-31
AU2024298849A1 (en) 2026-01-15
AR133391A1 (es) 2025-09-24
MX2026000917A (es) 2026-03-02
CN121752301A (zh) 2026-03-27
WO2025019952A1 (en) 2025-01-30
TW202510848A (zh) 2025-03-16
CO2026002011A2 (es) 2026-03-05
DOP2025000324A (es) 2026-01-30

Similar Documents

Publication Publication Date Title
ES3065771T3 (en) Substituted oxoisoindoline compounds for the treatment of cancer
IL307964A (he) טיפול משולב לטיפול בסרטן
IL316829A (he) מעכבי מנין-mll לטיפול בסרטן
IL289201A (he) תרכובות לטיפול בסרטן
RS67777B1 (sr) Postupak tretiranja tumora
GB202107994D0 (en) Treatment of cancer
IL305780A (he) שיטות לטיפול בסרטן
IL314687A (he) טיפול בסרטן
IL312155A (he) שיטה לטיפול בסרטן
CA3296090A1 (en) Psma-targeted radiopharmaceuticals for treatment of cancer
AU2024298849A1 (en) Psma-targeted radiopharmaceuticals for treatment of cancer
EP4452946A4 (en) CONNECTIONS FOR THE TREATMENT OF CANCER
GB202311976D0 (en) Treatment of cancer
GB202218181D0 (en) Treatment of cancer
IL272390A (he) שיטות לטיפול בסרטן
GB202201803D0 (en) Treatment of Cancer
GB201918815D0 (en) Treatment of cancer
IL312899A (he) טיפול משולב לטיפול בסרטן
IL300106A (he) תרפיית שילוב לטיפול בסרטן
GB202508597D0 (en) Compounds for the treatment of cancer
GB202018062D0 (en) Treatment of cancer
GB202008037D0 (en) Treatment of cancer
IL320482A (he) טיפול משולב לטיפול בסרטן
IL315444A (he) מערכת ביטוי לטיפול בסרטן
GB202013074D0 (en) Method of treatment for cancer